Pierre Fabre Laboratories and RedRidge Bio Announce a Drug Discovery and Co-development Partnership
Castres, France; Cambridge, Massachusetts, and Basel, Switzerland, 12 March 2025 – Pierre Fabre Laboratories and RedRidge Bio (“RedRidge”) today announced an exclusive R&D collaboration and license agreement to identify and develop biparatopic antibody (BPA) drug candidates against multiple targets. In line with Pierre Fabre Laboratories’ innovation strategy, the partnership’s therapeutic focus will be on precision oncology as well as dermatology and rare diseases.
Under the terms of the agreement, RedRidge will provide its capabilities to engineer, screen and characterize BPAs against an undisclosed portfolio of jointly nominated targets, while Pierre Fabre Laboratories will provide their drug development expertise to help drive two co-development programs through clinical development. RedRidge will hold exclusive commercial rights in the United States, Canada, and Japan for both programs, while Pierre Fabre Laboratories will hold exclusive rest-of-world rights. In addition, Pierre Fabre Laboratories will hold exclusive worldwide rights for a third program after a hand-off by RedRidge at a preclinical stage.
Financial terms of the agreement are not disclosed but include investment participation by Pierre Fabre Laboratories in RedRidge’s Series A financing that will be announced separately, as well as upfront, milestone and future sales royalty payments in addition to funded research payments for Pierre Fabre Laboratories’ worldwide program. RedRidge and Pierre Fabre Laboratories will share R&D costs for the co-development programs.
This strategic alliance attests to the RedRidge team’s expertise in innovation and drug discovery for a wide variety of therapeutic targets. We are thrilled to join forces with Pierre Fabre Laboratories as a highly experienced development partner and look forward to building a long-term partnership that synergistically leverages the capabilities of each company.
Alex Mayweg
hairperson of RedRidge’s board and a managing director at Versant Ventures
Pierre Fabre Laboratories are excited to enter into this agreement with RedRidge, which confirms our commitment to collaborate with innovative biotechnology companies. This partnership will allow us to capitalize on RedRidge’s cutting-edge expertise in biparatopic antibody drug discovery to deliver high quality clinical candidates on multiple targets addressing oncology, dermatology and rare diseases. It represents a significant milestone in the implementation of our strategy to enrich further our R&D pipeline.
Dr Francesco Hofmann
Head of Research and Development for Medical Care at Pierre Fabre
About RedRidge Bio
RedRidge Bio was incubated by Versant Ventures and the firm’s Ridgeline Discovery Engine in Basel Switzerland. RedRidge is an R&D company focused on the discovery and development of biparatopic antibodies for best-in-class efficacy. Biparatopic antibodies are multispecific therapeutic proteins that engage distinct epitopes on the same molecular target, which can offer myriad benefits compared to conventional antibodies, including superior functional antagonism, more efficient internalization, and fit-for-purpose agonism. With its leading platform that systematically elucidates desired candidates by leveraging high-throughput and big data, the company is developing a pipeline of therapeutic candidates in oncology and autoimmunity on both a fully proprietary basis and with its co-development partner, Pierre Fabre Laboratories.
Les Laboratoires Pierre Fabre :
Laure Bregeon-Sgandurra
+33 6 32 54 92 01
Laure.Sgandurra@pierre-fabre.com
RedRidge Bio :
Jonathan Fassberg
astr partners
+1 (917) 312-0822
jonathan.fassberg@astrpartners.com
